According to the 2026 Cancer Statistics, approximately 20 million people worldwide are newly diagnosed with cancer each year. Without effective control measures, this number is projected to double by 2030. A major challenge is the widespread lack of early diagnostic, prognostic, and treatment monitoring tests. For example, in some Southeast Asian countries like India, nearly 60% of cancer patients are diagnosed at the metastatic stage due to insufficient testing. Since metastasis accounts for the vast majority of cancer-related deaths and there are currently no effective therapies for metastatic cancer, improving early detection and monitoring is critical to reducing mortality.

At GeneVerify, Inc., our experts firmly believe that early detection and targeted intervention of key oncogenes can effectively inhibit cancer progression and metastasis. By leveraging these cutting-edge technologies, we aim to improve patient outcomes while also reducing overall healthcare costs.

We have developed a novel blood-based mRNA genomic technology, protected by five U.S. patents and validated through more than 200 original research publications in high-impact scientific journals.

Our blood-based mRNA genomic technology enables screening, early diagnosis, prognosis, treatment monitoring, and gene therapy across multiple cancer types. This technology has been validated through nine clinical trials conducted at leading hospitals in the USA, Japan, and India, consistently demonstrating 95% specificity and sensitivity.

Our team comprises over 50 medical scientists specializing in medical oncology, surgical oncology, pathology, radiation oncology, molecular biology, genetics, gene therapy, cancer biology, and biochemistry. Collectively, they bring 20 to 40 years of experience working in the United States, driving innovation and excellence in cancer research and treatment.

On January 25-27^th, 2024, we presented our data at the ASCO GU symposium (American Society of Clinical Oncology) meeting at San Francisco, California, USA. ASCO has more than 45,000 members worldwide. This paper was published in the Journal of Clinical Oncology January 29^th 2024.

https://ascopubs.org/doi/10.1200/JCO.2024.42.4_suppl.271

On April 5-10, 2024, we presented our data at the AACR meeting (American Association of Cancer Research) at San Diego, CA. AACR has more than 58,000 members from 141 countries (google search). This paper was published in the Journal “CANCER RESEARCH” March 22, 2024.

https://aacrjournals.org/cancerres/article/84/6_Supplement/2442/741209/Abstract-2442-Blood-based-novel-mRNA-genomic-test

On May 3-6, 2024 we presented our data at AUA (American Urology Association) at San Antonio, Texas. AUA has more than 25,000 members from 138 counties (google search). This paper was published in the Journal “Journal of Urology” May, 2024.

https://www.auajournals.org/doi/10.1097/01.JU.0001008896.93851.5b.05  

On May 30-June 3, 2025, we presented our data at the ASCO (American Society of Clinical Oncology) annual meeting at Chicago, Illinois, USA. ASCO has more than 45,000 members worldwide. This paper was published in the Journal of Clinical Oncology, May 28th 2025.

Real-time clinical validation of a blood cell-free, mRNA-based GeneVerify test for screening and early diagnosis of prostate cancer.

https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.3053

Key Advantages of GeneVerify’s Approach:

1. Improved Sensitivity Over Tissue Biopsy: While tissue biopsy remains the gold standard for cancer diagnosis, it has a false-negative rate of approximately 20%, leaving many cancers undiagnosed. GeneVerify has developed a blood-based mRNA genomic test with about 95% sensitivity, significantly enhancing early detection.
2. Early Detection When Traditional Methods Fail: Recent studies show that 25% of patients with normal pathological and clinical findings actually have cancer detectable through genetic testing. Since most cancer deaths result from metastasis, early detection is critical—up to 90% of patients diagnosed early can be cured or have their lives significantly prolonged.
3. Avoidance of Unnecessary Surgery: If tumors are slow growing, active surveillance may be appropriate. Published data suggest that up to 50% of surgeries could be avoided due to misdiagnosis, reducing patient risk and healthcare costs.
4. Personalized Prognosis Based on Genetic Profile: Aggressive tumors require more intensive treatment, while slow-growing tumors may need less aggressive intervention. Avoiding overtreatment can reduce mortality caused by unnecessary aggressive therapies.
5. Real-Time Treatment Monitoring: Genetic testing allows for close monitoring of therapy effectiveness, ensuring expensive treatments are working. This not only improves patient outcomes by preventing ineffective treatments but also saves millions in healthcare costs.
6. Advancing Gene-Based Therapies: We are initiating clinical trials for cancer therapies utilizing patented antisense technology and cutting-edge mRNA-LNP-CAR-T platforms. Our strategy combines gene-based diagnosis through genetic profiling with targeted inhibition of cancer-driving genes via antisense mechanisms.

At GeneVerify, Inc., we address the most critical challenges in patient care through a collaborative environment where teamwork and innovation drive breakthrough solutions.